1. Home
  2. LIN vs GRI Comparison

LIN vs GRI Comparison

Compare LIN & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Linde plc

LIN

Linde plc

HOLD

Current Price

$416.10

Market Cap

217.0B

Sector

Industrials

ML Signal

HOLD

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$0.52

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LIN
GRI
Founded
1879
2018
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
217.0B
4.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LIN
GRI
Price
$416.10
$0.52
Analyst Decision
Buy
Strong Buy
Analyst Count
12
2
Target Price
$500.36
$23.00
AVG Volume (30 Days)
2.9M
1.2M
Earning Date
10-31-2025
11-14-2025
Dividend Yield
1.44%
N/A
EPS Growth
13.37
N/A
EPS
14.94
N/A
Revenue
$33,504,000,000.00
N/A
Revenue This Year
$3.72
N/A
Revenue Next Year
$5.04
N/A
P/E Ratio
$27.86
N/A
Revenue Growth
1.45
N/A
52 Week Low
$387.78
$0.50
52 Week High
$486.38
$16.66

Technical Indicators

Market Signals
Indicator
LIN
GRI
Relative Strength Index (RSI) 53.55 22.14
Support Level $389.00 $0.50
Resistance Level $411.58 $2.17
Average True Range (ATR) 6.85 0.19
MACD 1.57 -0.16
Stochastic Oscillator 94.18 0.85

Price Performance

Historical Comparison
LIN
GRI

About LIN Linde plc

Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $33 billion in revenue in 2024.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: